AMGN240712C260000
- 46.69
- 0.000.00%
Amgen Newsroom
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Amgen Inc. (AMGN): Hedge Funds Are Bullish on This Blue Chip Dividend Stock Now
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $375
Jefferies analyst Michael Yee maintains $Amgen(AMGN.US)$ with a buy rating, and maintains the target price at $375.According to TipRanks data, the analyst has a success rate of 44.0% and a total
Beat the Market Like Zacks: Carvana, Adobe, Amgen in Focus
Ideaya Stock Jumps After Positive Study Data From Cancer Study
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga.
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
Shares of obesity drugmakers dipped on Wednesday after a study showed that patients who received Novo Nordisk’s NVO semaglutide, which is marketed as Wegovy (for obesity) and Ozempic (for diabetes), could develop a rare blinding eye disorder.
Amgen Inc. (NASDAQ:AMGN) Shares Could Be 42% Below Their Intrinsic Value Estimate
Amgen (AMGN.US) has obtained commercial rights for Evolocumab in Asia and other areas and has applied for listing in China.
On July 3rd, Amgen (AMGN.US) announced that it has reached an agreement with CSL Vifor to acquire commercial rights to Evolocumab in Asia and the Americas, including mainland China.
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ
What the Options Market Tells Us About Amgen
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 9 unusual trades.Delving into the details, we found 11% of traders were
Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints
Alvotech (ALVO) said Tuesday a confirmatory study for AVT03, a proposed biosimilar to Amgen's (AMGN) denosumab sold as Prolia and Xgeva, met its primary endpoints. The study aims to show clinical simi
Amgen Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 trades.If we consider the specifics of each trade,
Watch Now: ETF Edge on Reshoring Trends, Weight Loss Drugs and More
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Amgen Is Maintained at Buy by Argus Research
Amgen Is Maintained at Buy by Argus Research
Amgen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 8.83% Argus Research $300 → $340 Maintains Buy 06/14/2024 6.27% RBC Capital $328 → $332 Maintai